Literature DB >> 8083365

Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma.

D N Shapiro1, B G Jones, L H Shapiro, P Dias, P J Houghton.   

Abstract

The expression of the insulin-like growth factors (IGFs) and their receptors has been linked to cellular proliferation and tumorigenicity in a number of model systems. Since rhabdomyosarcoma cells express IGF-I receptors, an autocrine or paracrine loop involving this receptor and its ligands could be responsible in part for the growth characteristics of this tumor. To assess directly the role of the IGF-I receptor in rhabdomyosarcoma cell growth and tumorigenicity, a human alveolar rhabdomyosarcoma cell line with high IGF-I receptor expression was transfected with an amplifiable IGF-I receptor antisense expression vector. Four unique, transfected clones were analyzed and found to have reduced IGF-I receptor expression relative to the parental line. Integration of the antisense sequence was demonstrated by Southern blot analysis, and expression of antisense message in these clones was shown by S1 nuclease protection assay. Reduced IGF-I receptor surface expression in the transfectants was shown by decreased immunofluorescence with an IGF-I receptor monoclonal antibody and by decreased IGF-I binding as measured by Scatchard analysis. These clones had markedly reduced growth rates in vitro, impaired colony formation in soft agar, and failed to form tumors in immunodeficient mice when compared with vector-transfected clones. These results demonstrate that reduction of IGF-I receptor expression can inhibit both the in vitro and in vivo growth of a human rhabdomyosarcoma cell line and suggest a role for the IGF-I receptor in mediating neoplastic growth in this mesenchymally derived tumor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083365      PMCID: PMC295208          DOI: 10.1172/JCI117441

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation.

Authors:  S E Tollefsen; R Lajara; R H McCusker; D R Clemmons; P Rotwein
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

2.  Effect of an anti-insulin-like growth factor I receptor antibody on insulin-like growth factor II stimulation of DNA synthesis in human fibroblasts.

Authors:  C A Conover; P Misra; R L Hintz; R G Rosenfeld
Journal:  Biochem Biophys Res Commun       Date:  1986-09-14       Impact factor: 3.575

3.  Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation.

Authors:  S E Tollefsen; J L Sadow; P Rotwein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

4.  Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II.

Authors:  O M El-Badry; J A Romanus; L J Helman; M J Cooper; M M Rechler; M A Israel
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice.

Authors:  T Gansler; R Furlanetto; T S Gramling; K A Robinson; N Blocker; M G Buse; D A Sens; A J Garvin
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

6.  Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation.

Authors:  E V Prochownik; J Kukowska
Journal:  Nature       Date:  1986 Aug 28-Sep 3       Impact factor: 49.962

7.  Inducible production of c-fos antisense RNA inhibits 3T3 cell proliferation.

Authors:  J T Holt; T V Gopal; A D Moulton; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Stable reduction of thymidine kinase activity in cells expressing high levels of anti-sense RNA.

Authors:  S K Kim; B J Wold
Journal:  Cell       Date:  1985-08       Impact factor: 41.582

9.  Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann's thrombasthenia in whole blood by flow cytometry.

Authors:  L K Jennings; R A Ashmun; W C Wang; M E Dockter
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

10.  Insulin and insulinlike growth factor receptors and responses in cultured human muscle cells.

Authors:  M Shimizu; C Webster; D O Morgan; H M Blau; R A Roth
Journal:  Am J Physiol       Date:  1986-11
View more
  33 in total

Review 1.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 2.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 3.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

4.  Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells.

Authors:  You-Cheng Zhang; Xiao-Peng Wang; Ling-Yi Zhang; Ai-Lin Song; Zhi-Min Kou; Xu-Sheng Li
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

5.  Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation.

Authors:  W Li; Y X Jiang; J Zhang; L Soon; L Flechner; V Kapoor; J H Pierce; L H Wang
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

6.  Association of insulin receptor substrate 1 with simian virus 40 large T antigen.

Authors:  Z L Fei; C D'Ambrosio; S Li; E Surmacz; R Baserga
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

7.  Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.

Authors:  Liang Cao; Yunkai Yu; Isaac Darko; Duane Currier; Linnia H Mayeenuddin; Xiaolin Wan; Chand Khanna; Lee J Helman
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling.

Authors:  Wessen Maruwge; Pádraig D'Arcy; Annika Folin; Slavica Brnjic; Johan Wejde; Anthony Davis; Fredrik Erlandsson; Jonas Bergh; Bertha Brodin
Journal:  Onco Targets Ther       Date:  2008-11-01       Impact factor: 4.147

9.  The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs).

Authors:  Maria A Pantaleo; Annalisa Astolfi; Margherita Nannini; Guido Biasco
Journal:  J Transl Med       Date:  2010-11-15       Impact factor: 5.531

10.  Susceptibility to apoptosis in insulin-like growth factor-I receptor-deficient brown adipocytes.

Authors:  Angela M Valverde; Cecilia Mur; Michael Brownlee; Manuel Benito
Journal:  Mol Biol Cell       Date:  2004-09-08       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.